BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma Clinical Trial

Official title:

Bronchial Arterial Infusion Plus Bronchial Arterial Chemoembolization (BAI-BACE) for Advanced Lung Squamous Cell Carcinoma: a Multicenter Single-arm Phase II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06377735
• Other study ID #: CHEST-001
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2024
• Est. completion date: December 30, 2026

Study information

• Verified date: April 2024
• Source: Sun Yat-sen University
• Contact: Qunfang Zhou, MD
• Phone: 86 19868000115
• Email: zhouqun988509[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

Description:

This study is a multicenter, interventional study to explore the efficacy, safety of BAI-BACE as non-first-line therapy for advanced central squamous cell carcinoma. Lung cancer is the leading cause of cancer-related death worldwide. Owing to the insidious symptom, most patients (about 75 %) are diagnosed at the advanced stage of the disease and, thus, cannot undergo resection. The central squamous cell carcinoma accounts for 25% of all cases of lung cancer. The first-line standard treatment for advanced central squamous cell carcinoma is combined chemoradiotherapy, and chemoradiotherapy is usually as the second-line. However, treatment failure is noted in many patients, and those patients often face the limited therapy choice and poor prognosis. Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported to treat lung cancer in many hospitals in China. BAI, which use chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. The systemic toxicity of this surgery is low and tolerable. This study will provide clinical evidence that BACE-BAI will provide survival benefit for patients with advanced central squamous cell carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 85
• Est. completion date: December 30, 2026
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Squamous cell carcinoma diagnosed by pathology, and central location by imaging;

2. Age 18-80;

3. Patients failed to the standard first-line or second-line treatment;

4. Tumors limited in the chest;

5. Tumors were fed by bronchial artery through CTA reconstruction;

6. Patents received PD-1 inhibitor or not were also included;

7. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2;

8. Images within 2 weeks before inclusion;

9. Life expectancy more than 3 months;

10. Agreed to participated in this clinical trial;

11. Hemameba =3.0 x109/L, neutrophil =1.5x109/L, hemoglobin=10.0 g/L, platelet=100x 109/L, ALT; AST; bilirubin =1.5-fold normal, GFR=60ml/min.

Exclusion Criteria:

1. Contraindication of BAI or BACE;

2. Under 18 years or over 75 years;

3. extra-chest metastases;

4. Receiving other antitumor treatment;

5. Severe infection or pregnancy;

6. Severe Pulmonary fibrosis and pulmonary artery;

7. liver, kidney or poor physical conditions;

8. Severe pleural effusion or pericardial effusion;

9. Life expectancy less than 3 months.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma

Intervention

Procedure:
• BAI-BACE
Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.

Locations

Country	Name	City	State
China	Chinese PLA General hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free-Survival (PFS)	Progression was defined as progressive disease by independent radiologic review	12 months
Secondary	Overall survival (OS)	OS is the length of time from the date of inclusion until death from any cause.	24 months
Secondary	Objective response rate (ORR)	ORR, as determined based on tumor response according to RECIST 1.1, is defined as the proportion of all included patients whose best overall response (BOR) is either a complete response or partial response.	12 months
Secondary	Adverse events	Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations	24 months